Company
Headquarters: Suzhou, China
Employees: 272
CEO: Dr. Youzhi Tong
HK$956.6 Million
HKD as of Jan. 1, 2026
US$122.9 Million
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Kintor Pharmaceutical Limited, a biopharmaceutical company, engages in the research and development of drugs for the treatment of various cancers and other androgen receptor (AR) - related diseases in China, the United States, and Taiwan. The company's lead drug candidates include Proxalutamide, a small molecule second generation AR antagonist that is in various clinical trials for metastatic castration-resistant prostate cancer and breast cancer, as well as for the treatment of COVID-19; and Pyrilutamide, which is in various clinical trials for androgenetic alopecia and acne vulgaris. It also develops ALK-1 for the treatment of metastatic hepatocellular carcinoma and liver cancer; Detorsertib, a second-generation mTOR inhibitor for the treatment of metastatic solid tumours; GT1708F for the treatment of leukaemia and basal-cell carcinoma; and GT20029 for the treatment of androgenetic alopecia and acne vulgaris. The company was founded in 2009 and is headquartered in Suzhou, China.
Kintor Pharmaceutical Ltd has the following listings and related stock indices.
Stock: HKEX: 9939
Stock: OTC: KNTPF